263 filings
8-K
EPIX
Essa Pharma Inc
14 May 24
Results of Operations and Financial Condition
7:01am
10-Q
2024 Q2
EPIX
Essa Pharma Inc
Quarterly report
14 May 24
7:00am
S-8
EPIX
Essa Pharma Inc
5 Apr 24
Registration of securities for employees
4:57pm
8-K
EPIX
Essa Pharma Inc
7 Mar 24
Submission of Matters to a Vote of Security Holders
5:18pm
10-Q
2024 Q1
EPIX
Essa Pharma Inc
Quarterly report
13 Feb 24
7:01am
8-K
4wtd3kms uc
13 Feb 24
Results of Operations and Financial Condition
7:01am
8-K
pzz9rer
29 Jan 24
ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 2024 ASCO Genitourinary Cancers Symposium
9:15am
DEFA14A
99ve6udzrbf9o1jg8
26 Jan 24
Additional proxy soliciting materials
4:40pm
8-K
ik8 hq9ff
12 Dec 23
Results of Operations and Financial Condition
7:01am
8-K
zys20tudkkiny5l9hv
6 Nov 23
ESSA Pharma Enters into At-The-Market Equity Offering Sales Agreement
4:57pm
424B5
5i1g6c48903 sdxnul
3 Nov 23
Prospectus supplement for primary offering
9:44pm
8-K
qgpq3ly0l3c3noyynshe
26 Oct 23
ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 30th Annual Prostate Cancer Foundation Scientific Retreat
8:07pm
8-K
khbjz4y
23 Oct 23
ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the European Society of Medical Oncology 2023 Congress
4:19pm
EFFECT
0x18i3k8089rr73
11 Oct 23
Notice of effectiveness
12:15am
CORRESP
twk87jjvhmb
6 Oct 23
Correspondence with SEC
12:00am
CORRESP
f7oo3
6 Oct 23
Correspondence with SEC
12:00am
CORRESP
lwnh fwy3fs
3 Oct 23
Correspondence with SEC
12:00am